AMYLYX PHARMACEUTICALS INC
AMLXNASDAQ🏆 #1506 by market capEarnings Nov 5US Equity
$28.69▲ $0.61 (+2.17%)
After hours · at closeTrack AMLX
Get earnings, price moves & breaking news on Telegram
24h▲ 2.2%
7d▲ 0.3%
14d▲ 3.8%
30d▼ 1.9%
ytd▲ 137.3%
1y▲ 106.7%
🏦Market Cap
$3.60B
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
36
Weak
Trading Snapshot
- Day Range
- $28.25 – $29.07
- 52-Week Range
- $10.83 – $41.14
- Volume (shares)
- 70,079
- Avg Volume (shares)
- —
- Shares Outstanding
- 125.5M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -19.9
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.37
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +37.9%
AMYLYX PHARMACEUTICALS INC
AMLXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
51.8%▼ −44.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$153M▼ −51.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$123M▼ −26.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
94.6M▲ +37.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$221M▲ +$145M YoY
StockOtter · stockotter.spaceAbout AMYLYX PHARMACEUTICALS INC
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
36/100
Analyst Ratings
ⓘConsensus
Buy
18 analysts
Strong Buy9
Buy7
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.